Recessive Dystrophic Epidermolysis Bullosa Clinical Trial
Official title:
A Pilot, Open Study to Assess Efficacy and Safety of Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated Locally Advanced/Metastatic Squamous Cell Carcinoma
This pilot trial studies how rigsertib sodium works in treating patients with Recessive Dystrophic Epidermolysis bullosa (RDEB) with locally advanced Squamous Cell Carcinoma (SCC). Rigosertib may selectively target Epidermolysis bullosa (EB) cancer cells while leaving normal EB cells unaffected.
PRIMARY OBJECTIVES: I. To estimate the anti-tumor activity of oral or IV rigosertib in RDEB patients with advanced SCC that have failed prior standard of care, by determining the overall response rate (ORR) which is defined as the proportion of patients who achieve either a CR or a PR by RECIST v1.1 II. To evaluate the safety and tolerability of oral rigosertib administered either orally daily three weeks on, one week off or as 72h CIV infusions on day 1-3 of a two week-cycle for 8 cycles and then on day 1-3 of a 4 week cycle thereafter SECONDARY OBJECTIVES: I. Assess impact on quality of life (QoL) II. Biomarker analysis (to include markers of PI3K/Akt and PLK1 pathways) performed on all archival tissue from all patients EXPLORATORY OBJECTIVE: I. Exome sequencing of patient tumors before, during, and after treatment OUTLINE: Patients will receive rigosertib sodium as either oral capsules or IV infusion. Mode of application is determined by the responsible investigator depending on participant's needs, general condition, and possibility of ambulatory treatment or need of hospitalization. Patients will take oral rigosertib continuously for a total of three weeks of a four-week cycle (three weeks on, one week off drug). For IV treatment, patients will receive rigosertib IV administered as a 72-hr continuous infusion on Days 1, 2 and 3 of a 2-week cycle for the first eight 2-week cycles, then on Days 1, 2 and 3 of a 4-week cycle thereafter. Patients will receive treatment over a 52 week period. After completion of study treatment, patients are followed periodically every 3 months over a 12 month period. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02493816 -
Safety Study of Gene-modified Autologous Fibroblasts in Recessive Dystrophic Epidermolysis Bullosa
|
Phase 1 | |
Completed |
NCT04599881 -
A Study of PTR-01 in Recessive Dystrophic Epidermolysis Bullosa
|
Phase 2 | |
Completed |
NCT04520022 -
Safety and Effectiveness Study of Allogeneic Umbilical Cord Blood-derived Mesenchymal Stem Cell in Patients With RDEB
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03632265 -
Study of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
|
Phase 3 | |
Recruiting |
NCT05944250 -
A Pilot Study to Evaluate a Temporary Skin Substitute (Spincare® Matrix) for Wound Healing in RDEB Patients
|
N/A | |
Recruiting |
NCT04917887 -
Long-Term Follow-up Protocol
|
||
Completed |
NCT04917874 -
A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa
|
Phase 3 | |
Not yet recruiting |
NCT04285294 -
Molecular Signatures of Cutaneous Squamous Cell Carcinoma During Recessive Dystrophic Epidermolysis Bullosa
|
||
Active, not recruiting |
NCT04213261 -
A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa
|
Phase 3 | |
Active, not recruiting |
NCT02323789 -
Mesenchymal Stromal Cells in Adults With Recessive Dystrophic Epidermolysis Bullosa
|
Phase 1/Phase 2 | |
Recruiting |
NCT01874769 -
Study of Immune Tolerance and Capacity for Wound Healing of Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
|
N/A | |
Recruiting |
NCT03392909 -
Intravenous Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
|
Phase 1/Phase 2 | |
Completed |
NCT03752905 -
A Phase 1/2 Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
|
Phase 1/Phase 2 | |
Terminated |
NCT02984085 -
Clinical Trial to Assess Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified in Patients With RDEB.
|
Phase 1/Phase 2 | |
Completed |
NCT04227106 -
Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
|
Phase 3 | |
Completed |
NCT02698735 -
Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Nonsense Mutation Patients
|
Phase 1/Phase 2 | |
Completed |
NCT03012191 -
Gentamicin for RDEB
|
Phase 1/Phase 2 | |
Completed |
NCT03529877 -
Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa
|
Phase 1/Phase 2 | |
Completed |
NCT05143190 -
Extension Study to PTR-01-002 (A Study in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previously Treated With PTR-01)
|
Phase 2 | |
Completed |
NCT04491604 -
Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB
|
Phase 3 |